Epigenetic Therapy for Epithelioid Sarcoma

Scott B. Rothbart, Stephen B. Baylin

Research output: Contribution to journalArticlepeer-review

Abstract

Tazemetostat is the first epigenetic therapy to gain FDA approval in a solid tumor. This lysine methyltransferase inhibitor targets EZH2, the enzymatic subunit of the PRC2 transcriptional silencing complex. Tumors with mutations in subunits of the SWI/SNF chromatin remodeling complex, inclusive of most epithelioid sarcomas, are sensitive to EZH2 inhibition.

Original languageEnglish (US)
Pages (from-to)211
Number of pages1
JournalCell
Volume181
Issue number2
DOIs
StatePublished - Apr 16 2020

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Epigenetic Therapy for Epithelioid Sarcoma'. Together they form a unique fingerprint.

Cite this